For the first time in more than a decade, adults living with migraine have a fresh, evidence-based roadmap for preventing attacks. In September 2026, the American Academy of Neurology (AAN) and the American Headache Society (AHS) jointly released updated clinical practice guidelines on migraine prevention in adults, replacing recommendations that had stood since 2012. The American Academy of Family Physicians endorsed the new framework, signaling broad support across primary care and neurology.
The update matters because so much has changed. Since the last guideline, an entirely new class of migraine-specific medications targeting calcitonin gene-related peptide (CGRP) has come to market, and long-term data on older preventive drugs have accumulated. Research suggests these newer therapies can meaningfully reduce migraine days for many patients who previously had few tolerable options.
Why Prevention Matters
Migraine is far more than a bad headache. According to the U.S. National Institute of Neurological Disorders and Stroke, migraine affects roughly 1 in 6 American adults, and the Global Burden of Disease Study ranks migraine among the leading causes of years lived with disability worldwide. Repeated attacks can disrupt work, sleep, mood, and relationships — and frequent acute medication use can, paradoxically, worsen the condition.
Yet as Matthew Robbins, MD, President of the American Headache Society, told reporters, migraine remains “woefully undertreated.” A central goal of the 2026 guideline is to help clinicians and patients recognize when preventive therapy is warranted and to broaden the menu of choices they consider.
Who Should Consider Preventive Treatment?
The new guideline outlines several thresholds at which clinicians should discuss preventive medication with an adult who has migraine:
- Four or more migraine days per month, or
- Four or more moderate-to-severe headache days per month, or
- Migraine attacks that significantly interfere with work, school, family, or daily activities, even if they occur less often.
Prevention is also considered when acute treatments are poorly tolerated, contraindicated, ineffective, or overused (a pattern that can trigger medication-overuse headache).
What’s New: CGRP-Targeted Therapies
The most substantial change from 2012 is the inclusion of medications developed specifically to block the CGRP pathway, which plays a central role in migraine pain signaling. These fall into two broad groups:
CGRP Monoclonal Antibodies (Injectables)
Erenumab, fremanezumab, galcanezumab, and eptinezumab are given by subcutaneous injection monthly or quarterly (eptinezumab is intravenous). Randomized trials published in journals including The Lancet, JAMA Neurology, and The New England Journal of Medicine have shown these agents can reduce monthly migraine days compared with placebo, with tolerability profiles that many patients find easier than older options.
Gepants (Oral CGRP Blockers)
Atogepant and rimegepant are small-molecule CGRP receptor antagonists taken by mouth. Rimegepant is unusual in that it can be used both to treat an attack and, on alternate days, to prevent one — a dual role no earlier medication offered.
Established Preventives Still Have a Role
The guideline does not abandon older, well-studied options. Medications such as topiramate, propranolol, and other beta-blockers, along with certain antidepressants (for example, amitriptyline) and, in select patients, onabotulinumtoxinA (Botox) for chronic migraine, retain a place in preventive care. Cost, insurance coverage, and long-standing clinical experience mean these drugs remain first-line for many patients, particularly in primary care settings.
Non-drug approaches also feature in the broader migraine literature that informs the guideline. Studies indicate that consistent sleep, hydration, regular meals, aerobic exercise, and evidence-based behavioral therapies such as cognitive behavioral therapy, biofeedback, and mindfulness training can reduce attack frequency for some individuals.
A Shared-Decision Framework
Perhaps the most important shift is philosophical. Rather than a rigid ladder of drug choices, the new guideline emphasizes shared decision-making. Clinicians are encouraged to weigh:
- Strength of evidence for each option
- Side-effect profile and comorbidities (for example, mood, cardiovascular, or gastrointestinal conditions)
- Route of administration — daily pill, monthly injection, quarterly infusion
- Cost, insurance coverage, and access
- Reproductive plans, since some preventives are not recommended during pregnancy
- Patient preferences and quality-of-life priorities
This individualized approach reflects the reality that migraine is heterogeneous. What works reliably for one person may be unhelpful — or intolerable — for another.
How to Prepare for a Conversation with Your Clinician
Research suggests that keeping a simple migraine diary for four to eight weeks can meaningfully improve care. Useful details to track include:
- Number of headache days per month and how many meet migraine criteria (moderate-to-severe pain, nausea, light or sound sensitivity, or aura)
- Time of onset, duration, and triggers you notice (sleep changes, menstrual cycle, weather, specific foods, stress)
- All medications used, including over-the-counter analgesics — this helps identify medication-overuse patterns
- How attacks affect work, caregiving, exercise, and sleep
Bring this record to your appointment. It gives your clinician the raw material needed to match a preventive option to your pattern.
Realistic Expectations
Studies indicate that a “successful” preventive typically reduces monthly migraine days by 50% or more for a subset of patients, not that it eliminates migraine entirely. Most oral preventives require eight to twelve weeks at a therapeutic dose before their full effect can be judged, while CGRP monoclonal antibodies often show benefit within one to three months. If a first choice does not help, the guideline supports trying another — sometimes from a different class — rather than concluding that prevention itself has failed.
The Bottom Line
The 2026 AAN/AHS guideline reframes migraine prevention as a modern, individualized conversation with a wider menu of options than existed in 2012. For adults whose lives are shaped by frequent or disabling attacks, that is a meaningful advance. If you experience four or more headache days per month, or attacks that repeatedly derail your day, it may be worth asking your clinician whether an updated preventive plan is right for you.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.